KEVIN WALDO: Open Payments
NPI 1356018543 · WARSAW, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,159 in 59 payments from 15 companies in 2025. Trend: 2023 $1,964 · 2024 $2,300 · 2025 $1,159
Food & beverage: $1,159
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $482 |
| Janssen Biotech, Inc. | 8 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| QOL Medical, LLC | 4 | $70 |
| GENZYME CORPORATION | 2 | $50 |
| Madrigal Pharmaceuticals | 2 | $49 |
| VIVUS LLC | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: TREMFYA, RINVOQ, CREON, DUPIXENT, Sucraid, EOHILIA, LINZESS, REZDIFFRA.
Industry payments across IN — which companies pay providers there.
